Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Cost of Revenue: 2019-2024

Historic Cost of Revenue for Catalyst Pharmaceuticals (CPRX) over the last 6 years, with Dec 2024 value amounting to $68.8 million.

  • Catalyst Pharmaceuticals' Cost of Revenue rose 17.52% to $22.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $82.8 million, marking a year-over-year increase of 31.44%. This contributed to the annual value of $68.8 million for FY2024, which is 32.48% up from last year.
  • According to the latest figures from FY2024, Catalyst Pharmaceuticals' Cost of Revenue is $68.8 million, which was up 32.48% from $52.0 million recorded in FY2023.
  • In the past 5 years, Catalyst Pharmaceuticals' Cost of Revenue registered a high of $68.8 million during FY2024, and its lowest value of $17.0 million during FY2020.
  • Its 3-year average for Cost of Revenue is $51.7 million, with a median of $52.0 million in 2023.
  • Data for Catalyst Pharmaceuticals' Cost of Revenue shows a peak YoY soared of 57.16% (in 2022) over the last 5 years.
  • Over the past 5 years, Catalyst Pharmaceuticals' Cost of Revenue (Yearly) stood at $17.0 million in 2020, then grew by 28.43% to $21.9 million in 2021, then spiked by 57.16% to $34.4 million in 2022, then surged by 51.10% to $52.0 million in 2023, then soared by 32.48% to $68.8 million in 2024.